Trial Profile
A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg Dose of TH9507, a Growth Hormone Releasing Factor Analog, in HIV Patients With Excess of Abdominal Fat Accumulation
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Apr 2023
Price :
$35
*
At a glance
- Drugs Tesamorelin (Primary)
- Indications HIV-associated lipodystrophy syndrome
- Focus Registrational; Therapeutic Use
- Sponsors Theratechnologies
- 22 Feb 2023 Results (n=400) assessing whether treatment with tesamorelin was associated with changes in Metabolic Syndrome classification from 2 Phase III trials of tesamorelin, presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023.
- 22 Feb 2023 Results presented in the Thera Technologies media release.
- 22 Feb 2023 According to Thera Technologies media release, the company presented a data suggesting that tesamorelin may improve metabolic profiles in people with HIV (PWHIV) by reducing excess visceral abdominal fat (EVAF) at the 30th Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, Washington.